Dortmund, Germany, December 3, 2013 / B3C newswire / -Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”
About Protagen
PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.
Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T: +49 (0) 231 9742 6300
F: +49 (0) 231 9742 6301
This email address is being protected from spambots. You need JavaScript enabled to view it.
Press Inquiries
Dr. Georg Lautscham
CBO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T:+49 (0) 231 9742 6300
F:+49 (0) 231 9742 6301
This email address is being protected from spambots. You need JavaScript enabled to view it.